Saravut Weroha

Hematology | Oncology

200 1st St Sw
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Factors affecting trainees' preferred timing of clinical clerkships during MD-PhD training.

Factors affecting trainees' preferred timing of clinical clerkships during MD-PhD training.

Journal: medRxiv : the preprint server for health sciences

Published: May 25, 2026

Factors affecting trainees' preferred timing of clinical clerkships during MD-PhD training.

Factors affecting trainees' preferred timing of clinical clerkships during MD-PhD training.

Journal: medRxiv : the preprint server for health sciences

Published: May 25, 2026

Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.

Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.

Journal: Gynecologic oncology

Published: May 05, 2026

Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis.

Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis.

Journal: JCO oncology advances

Published: April 01, 2026

Clinical relevance of transcriptome profiling for assessing prognosis, platinum insensitivity, and precision therapeutics in endometrial cancer.

Clinical relevance of transcriptome profiling for assessing prognosis, platinum insensitivity, and precision therapeutics in endometrial cancer.

Journal: Gynecologic oncology

Published: March 25, 2026

CTPS1 is an unexplored vulnerability in breast and ovarian cancer.

CTPS1 is an unexplored vulnerability in breast and ovarian cancer.

Journal: Theranostics

Published: March 19, 2026

Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.

Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.

Journal: Science translational medicine

Published: January 14, 2026

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2025

N-Glycosylation of AXL Receptor Tyrosine Kinase Regulates Its Stability, Phosphorylation, and Oncogenic Function.

N-Glycosylation of AXL Receptor Tyrosine Kinase Regulates Its Stability, Phosphorylation, and Oncogenic Function.

Journal: Molecular & cellular proteomics : MCP

Published: December 05, 2025

Prognostic value of perioperative circulating tumor DNA (ctDNA) in endometrial cancer with high-risk features: a prospective observational study.

Prognostic value of perioperative circulating tumor DNA (ctDNA) in endometrial cancer with high-risk features: a prospective observational study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: November 16, 2025

Mucinous ovarian neoplasm - outcomes of a rare tumor.

Mucinous ovarian neoplasm - outcomes of a rare tumor.

Journal: Gynecologic oncology reports

Published: October 06, 2025

MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis.

MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis.

Journal: Gynecologic oncology reports

Published: October 01, 2025

Showing 1-12 of 95

Last Updated: 09/26/2026